Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

High Mobility Group Protein B1 Therapeutic Pipeline Market Review, H2 2016

Thursday, October 20, 2016 0:17
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Pipeline Review, H2 2016’, provides in depth analysis on High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted pipeline therapeutics.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693279-high-mobility-group-protein-review-h2-2016

The report provides comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics development and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) 
- The report reviews High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693279-high-mobility-group-protein-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) Overview 6 
Therapeutics Development 7 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Products under Development by Stage of Development 7 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Products under Development by Therapy Area 8 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Products under Development by Indication 9 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Pipeline Products Glance 10 
Early Stage Products 10 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Products under Development by Companies 11 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Products under Development by Universities/Institutes 13 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Therapeutics Assessment 15 
Assessment by Monotherapy/Combination Products 15 
Assessment by Mechanism of Action 16 
Assessment by Route of Administration 18 
Assessment by Molecule Type 19 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Companies Involved in Therapeutics Development 21 
Affibody AB 21 
Bio3 Research S.r.l 22 
Dicerna Pharmaceuticals, Inc. 23 
Evec, Inc. 24 
Ribomic Inc. 25 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Drug Profiles 26 
Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis – Drug Profile 28 
Product Description 28 
Mechanism Of Action 28 
R&D Progress 28 
CTR-1 – Drug Profile 29 
Product Description 29 
Mechanism Of Action 29 
R&D Progress 29 
CTR-2 – Drug Profile 30 
Product Description 30 
Mechanism Of Action 30 
R&D Progress 30 
CTR-3 – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
CTR-4 – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
EV-007156 – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
Monoclonal Antibody to Inhibit HMGB1 for Brain Infarction, Influenza A Infections and Parkinson’s Disease – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
RBM-005 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
Recombinant Protein for Oncology – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
Recombinant Protein to Inhibit HMGB1 for Stroke – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Dormant Projects 38 
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – Featured News & Press Releases 39 
Nov 16, 2012: Bio3 Research Receives Hong Kong Patent For HMGB1 Antibodies To Treat Vascular Diseases 39 
Appendix 40 
Methodology 40 
Coverage 40 
Secondary Research 40 
Primary Research 40 
Expert Panel Validation 40 
Contact Us 40 
Disclaimer 41

List of Tables 
Number of Products under Development for, H2 2016 7 
Number of Products under Development by Therapy Area, H2 2016 8 
Number of Products under Development by Indication, H2 2016 9 
Comparative Analysis by Early Stage Products, H2 2016 10 
Number of Products under Development by Companies, H2 2016 11 
Products under Development by Companies, H2 2016 12 
Number of Products under Investigation by Universities/Institutes, H2 2016 13 
Products under Investigation by Universities/Institutes, H2 2016 14 
Assessment by Monotherapy/Combination Products, H2 2016 15 
Number of Products by Stage and Mechanism of Action, H2 2016 17 
Number of Products by Stage and Route of Administration, H2 2016 18 
Number of Products by Stage and Molecule Type, H2 2016 20 
Pipeline by Affibody AB, H2 2016 21 
Pipeline by Bio3 Research S.r.l, H2 2016 22 
Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 23 
Pipeline by Evec, Inc., H2 2016 24 
Pipeline by Ribomic Inc., H2 2016 25 
Dormant Projects, H2 2016 38

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693279

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.